News & Updates

Show Multimedia Only
HCT treatment tied to lower cancer risk, except skin cancer

HCT treatment tied to lower cancer risk, except skin cancer

26 May 2023
COVID vax fortifies defences against emerging omicron variants in previously infected youths

COVID vax fortifies defences against emerging omicron variants in previously infected youths

26 May 2023 byJairia Dela Cruz

For children and adolescents who have been previously exposed to SARS-CoV-2 infection, vaccination with BNT162b2 appears to provide additional protection against omicron BA.4 or BA.5 and XBB variant infections, according to a study from Singapore.

COVID vax fortifies defences against emerging omicron variants in previously infected youths

26 May 2023
Serum osteopontin levels predicts response to treatment in unresectable HCC

Serum osteopontin levels predicts response to treatment in unresectable HCC

25 May 2023

Among patients with unresectable hepatocellular carcinoma (HCC) scheduled to receive standard combination therapy with atezolizumab plus bevacizumab, those with high levels of serum osteopontin at baseline are likely to have poor response to treatment, as shown in a study.

Serum osteopontin levels predicts response to treatment in unresectable HCC

25 May 2023
Paediatric TB care riddled with uncertainty, study says

Paediatric TB care riddled with uncertainty, study says

25 May 2023 byJairia Dela Cruz

Uncertainty weighs heavily on managing tuberculosis (TB) infection in children, with multi-level factors influencing the decision-making regarding testing and treatment.

Paediatric TB care riddled with uncertainty, study says

25 May 2023
Sofosbuvir/velpatasvir effective, safe for paediatric HCV

Sofosbuvir/velpatasvir effective, safe for paediatric HCV

25 May 2023
2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

25 May 2023 byJairia Dela Cruz

Both the 2-dose and 3-dose vaccination schedules of the four-component meningococcal serogroup B vaccine (4CMenB) appear to provide protection against a panel epidemiologically relevant strains in adolescents and young adults, according to a phase III study presented at ESPID 2023.

2-dose, 3-dose vax schedules active against several meningococcal serogroup B strains

25 May 2023